Publications

Featured Articles

Rectangle 61 (Stroke)

Evaluating the Potential of Cyclodextrins in Reducing Aggregation of Antibody–Drug Conjugates with Different Payloads

Johann, F., et al., J Pharm Sci, 2024, 26:S0022-3549(24)00148-5
Rectangle 61 (Stroke)

DNA Released by Adeno-Associated Virus Strongly Alters Capsid Aggregation Kinetics in a Physiological Solution

Jarand, Curtis W., et al., Biomacromolecules, 2024, 25 (5), 2890-2901
Rectangle 61 (Stroke)

Interfacial Pressure and Viscoelasticity of Antibodies and Their Correlation to Long-Term Stability in Formulation

Pham, Kiet, et al. The Journal of Physical Chemistry B 2023 127 (45), 9724-9733

Rectangle 61 (Stroke)

Backgrounded Membrane Imaging—A Valuable Alternative for Particle Detection of Biotherapeutics?

Schleinzer, Franziska, et al. Journal of Pharmaceutical Innovation, 2023, s12247-023-09734-5
Rectangle 61 (Stroke)

Physical Compatibility of Y-site Pediatric Drug Administration: A Call for Question of US Pharmacopeia Standards?

Emma L. Ross, et al. The Journal of Pediatric Pharmacology and Therapeutics 2023 Feb, 28 (1): 84–92
Rectangle 61 (Stroke)

Particles in Biopharmaceutical Formulations, Part 2: An Update on Analytical Techniques and Applications for Therapeutic Proteins, Viruses, Vaccines and Cells

Roesch A, et al. J Pharm Sci. 2021 Dec, S0022-3549(21)00689-4
Rectangle 61 (Stroke)

Miniaturized Forced Degradation of Therapeutic Proteins and ADCs by Agitation-Induced Aggregation using Orbital Shaking of Microplates

Johann F, et al. J Pharm Sci. 2021 Sept, S0022-3549(21)00497-4
Rectangle 61 (Stroke)

Analysis of Aggregates and Particles

Cheng Y, Saggu M, and Thomas JC, Protein Instability at Interfaces During Drug Product Development, 2021 Feb, pp 199-266
Rectangle 61 (Stroke)

Surfactant Impact on Interfacial Protein Aggregation and Utilization of Surface Tension To Predict Surfactant Requirements for Biological Formulations

Vargo KB, Wu Z, and Gupta S. Mol Pharm. 2021 Jan, 18(1):148-157
Rectangle 61 (Stroke)

Developability Assessment for Monoclonal Antibody Drug Candidates: A Case Study

Garripelli VK, et al., Pharm Dev Technol, 2021 Jan, 26(1):11-20